Ibritumomab: serious cutaneous reactions.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy
D000911:Antibodies, Monoclonal